A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs MK 1308 (Primary) ; Pembrolizumab
- Indications Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 27 Nov 2019 Planned End Date changed from 16 Feb 2023 to 24 Oct 2022.
- 27 Nov 2019 Planned primary completion date changed from 16 Feb 2023 to 24 Oct 2022.
- 31 Jul 2019 Planned End Date changed from 8 Mar 2023 to 16 Feb 2023.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History